Pharmalot.. Pharmalittle.. Good Morning.. Catching up on Valeant, Allergan, Novartis and..
Hello, everyone, and how are you today? We are doing fine, thank you, especially given that this is the middle of the week. Perhaps you can relate. Of course, we will forge ahead, as always, since the alternatives appear bleak. This calls for a cup of stimulation and we invite you to join us. By the way, we would like to note that, next week, we will shift over to Stat, so please adjust your reading habits. Meanwhile, here are some tidbits. Have a smashing day…
Valeant Pharmaceuticals is offering discounts and, in some cases, giving dermatological drugs away for free in a bid to retain market share; The Japanese health ministry plans to censure Novartis for failing to report serious side effects from some of its drugs within a certain period of time; Pfizer and Allergan are moving toward a plan to make Brent Saunders chief executive officer if the two drug giants reach a takeover agreement; and India has taken step to ease norms for testing and clinical trials needed for introduction of drugs already approved in other countries.